Insulinoma staging: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}}{{ADS}} | {{CMG}}; {{AE}}{{ADS}} | ||
==Overview== | ==Overview== | ||
The staging had been done according to American Joint Cancer Committee (AJCC) 7th edition 2010. | The staging had been done according to American Joint Cancer Committee (AJCC) 7th edition 2010. Being a [[pancreatic neuroendocrine tumor]], it is also staged by European Neuroendocrine Tumor Society (ENETS). In its new 8th edition of AJCC which is planned to be published on January 1, 2018; AJCC had developed a modified ENETS (mENETS) staging classification. | ||
==Staging== | ==Staging== | ||
=== [[American Joint Committee on Cancer|American Joint Cancer Committee]] ([[AJCC]]) 7th edition 2010 | === [[American Joint Committee on Cancer|American Joint Cancer Committee]] ([[AJCC]]) 7th edition 2010 classification === | ||
The staging of [[malignant]] insulinoma being a [[pancreatic neuroendocrine tumor]] may be classified into several | The staging of [[malignant]] insulinoma being a [[pancreatic neuroendocrine tumor]] may be classified into several sub types based on [[American Joint Committee on Cancer|American Joint Cancer Committee]] ([[AJCC]]) 7th edition 2010: <ref name="pmid27646952">{{cite journal| author=Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C et al.| title=Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. | journal=J Clin Oncol | year= 2017 | volume= 35 | issue= 3 | pages= 274-280 | pmid=27646952 | doi=10.1200/JCO.2016.67.8193 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27646952 }} </ref><ref name="pmid25816036">{{cite journal| author=Yang M, Zeng L, Zhang Y, Wang WG, Wang L, Ke NW et al.| title=TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. | journal=Medicine (Baltimore) | year= 2015 | volume= 94 | issue= 12 | pages= e660 | pmid=25816036 | doi=10.1097/MD.0000000000000660 | pmc=4554009 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25816036 }} </ref> | ||
{| class="wikitable" align="right" | {| class="wikitable" align="right" | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Stage''' | | style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Stage''' | ||
| Line 243: | Line 243: | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
| |||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 15:07, 5 December 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma staging On the Web |
|
American Roentgen Ray Society Images of Insulinoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
The staging had been done according to American Joint Cancer Committee (AJCC) 7th edition 2010. Being a pancreatic neuroendocrine tumor, it is also staged by European Neuroendocrine Tumor Society (ENETS). In its new 8th edition of AJCC which is planned to be published on January 1, 2018; AJCC had developed a modified ENETS (mENETS) staging classification.
Staging
American Joint Cancer Committee (AJCC) 7th edition 2010 classification
The staging of malignant insulinoma being a pancreatic neuroendocrine tumor may be classified into several sub types based on American Joint Cancer Committee (AJCC) 7th edition 2010: [1][2]
| Stage | T | N | M |
| IA | T1 | N0 | M0 |
| IB | T2 | N0 | M0 |
| IIA | T3 | N0 | M0 |
| IIB | T1-3 | N1 | M0 |
| III | T4 | Any N | M0 |
| IV | Any T | Any N | M1 |
| AJCC 2010 | |||
| T | T1 | <2 cm in greatest dimension | |
|---|---|---|---|
| T2 | >2 cm in greatest dimension | ||
| T3 | Beyond the pancreas but without involvement of the superior mesenteric artery | ||
| T4 | Involvement of the celiac axis or superior mesenteric artery (unresectable tumor) | ||
| N | N0 | No regional lymph node metastasis | |
| N1 | Regional lymph node metastasis | ||
| M | M0 | No distant metastasis | |
| M1 | Distant metastasis | ||
European Neuroendocrine Tumor Society (ENETS) classification:
Being a pancreatic neuroendocrine tumor, it is also staged by European Neuroendocrine Tumor Society (ENETS) as: [1][2]
| Stage | T | N | M |
| I | T1 | N0 | M0 |
| IIA | T2 | N0 | M0 |
| IIB | T3 | N0 | M0 |
| IIIA | T4 | N0 | M0 |
| III B | Any T | N1 | M0 |
| IV | Any T | Any N | M1 |
| ENETS | |||
| T | T1 | Tumor limited to pancreas, <2 cm | |
|---|---|---|---|
| T2 | Tumor limited to pancreas, 2-4 cm | ||
| T3 | >4cm, or invading the duodenum or common bile duct | ||
| T4 | Tumor invades adjacent structures | ||
| N | N0 | No regional lymph node metastasis | |
| N1 | Regional lymph node metastasis | ||
| M | M0 | No distant metastasis | |
| M1 | Distant metastasis | ||
WHO 2010 classification system
- WHO classification system combined differentiation and grading characteristics to classify the belligerence of a pancreatic neuroendocrine tumor.
- The aggressiveness of tumor was expressed in form of mitotic count and staining of a nuclear antigen called Ki-67: [3][4]
| Grade of tumor | Mitotic Count(Mitoses per 10 high powerfields) | Expression of Ki 67 |
| Grade 1 | <2 | ≤3% |
| Grade 2 | 2-10 | 3-20% |
| Grade 3 | >20 | >20% |
- Grade 1 and 2 tumors were classified as neuroendocrine neoplasm (NET) and grade 3 were classified as neuroendocrine carcinoma (NEC).
- In its new 8th edition of AJCC which is planned to be published on January 1, 2018; AJCC had developed a modified ENETS (mENETS) staging classification:[1]
| Stage | T | N | M |
| IA | T1 | N0 | M0 |
| IB | T2 | N0 | M0 |
| IIA | T3 | N0 | M0 |
| IIB | T1-3 | N1 | M0 |
| III | T4 | Any N | M0 |
| IV | Any T | Any N | M1 |
| mENETS | ||
| T | T1 | Tumor limited to pancreas, <2 cm |
|---|---|---|
| T2 | Tumor limited to pancreas, 2-4 cm | |
| T3 | >4cm, or invading the duodenum or common bile duct | |
| T4 | Tumor invades adjacent structures | |
| N | N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis | |
| M | M0 | No distant metastasis |
| M1 | Distant metastasis | |
References
- ↑ 1.0 1.1 1.2 Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C; et al. (2017). "Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems". J Clin Oncol. 35 (3): 274–280. doi:10.1200/JCO.2016.67.8193. PMID 27646952.
- ↑ 2.0 2.1 Yang M, Zeng L, Zhang Y, Wang WG, Wang L, Ke NW; et al. (2015). "TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution". Medicine (Baltimore). 94 (12): e660. doi:10.1097/MD.0000000000000660. PMC 4554009. PMID 25816036.
- ↑ Bosman, F. T. (2010). WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer. ISBN 978-9283224327.
- ↑ Sun J (2017). "Pancreatic neuroendocrine tumors". Intractable Rare Dis Res. 6 (1): 21–28. doi:10.5582/irdr.2017.01007. PMC 5359348. PMID 28357177.